COMPANY

Aqua Medical

HQ: Pleasanton, CA source · aquaendoscopy.com ↗ · West Coast

Keywords: metabolic Type-2 Diabetes Mellitus Diabetes Mellitus Type 2 RF Vapor Ablation

Location: Pleasanton, CA · source · Oct 14, 2026

Profile checked Oct 10, 2026

Raises and deals from press releases

Raise Series B · amount not disclosed · announced Sep 24, 2026 Company release ↗
Source quote
- Sep 24, 2026 · Company release ↗
  “PLEASANTON, Calif., [September 24, 2026] — Aqua Medical, Inc., a clinical-stage medical technology company advancing Endoscopic Metabolic Restoration for the treatment of Type 2 diabetes, today announced the closing of a Series B financing led by Nashville”

From the company’s own releases; this list is partial. All raises and deals

Sep 24, 2026 Raise Series B · amount not disclosed source ↗
Apr 1, 2026 Trial start Not phased (device or behavioral study): A U.S. Pilot Human Investigation of RadiofrEquency Vapor Ablation System to Evaluate Safety, TOleRability, and Effectiveness for Proximal Intestinal Mucosal Ablation in Patients With Type 2 Diabe source ↗
Aug 8, 2025 FDA FDA 510(k) clearance: Aqua Medical RF Vapor Ablation System — K251226, Aug 8, 2025. Applicant at approval: Aqua Medical, Inc. source ↗
Dec 12, 2024 FDA FDA 510(k) clearance: Aqua Medical RF Vapor Ablation System — K241271, Dec 12, 2024. Applicant at approval: Aqua Medical, Inc. source ↗
Nov 14, 2024 Trial start Not phased (device or behavioral study): RF Vapor Ablation Retreatment of Duodenal Mucosa in Non-responders With Type-2 Diabetes Mellitus source ↗
Oct 1, 2024 Trial start Not phased (device or behavioral study): Safety, Tolerability, and Effectiveness of Duodenal Mucosal RF Vapor Ablation for Insulin Elimination in Type-2 Diabetes source ↗
Sep 2, 2023 Trial start Not phased (device or behavioral study): Study of Duodenal Mucosal RF Vapor Ablation in Subjects With Type-2 Diabetes Mellitus source ↗

Dec 31, 2026 (ESTIMATED) · Not phased · A U.S. Pilot Human Investigation of RadiofrEquency Vapor Ablation System to Evaluate Safety, TOleRability, and Effectiveness for Proximal Intestinal Mucosal Ablation in Patients With Type 2 Diabetes M · NCT07355270
Jun 30, 2027 (ESTIMATED) · Not phased · Safety, Tolerability, and Effectiveness of Duodenal Mucosal RF Vapor Ablation for Insulin Elimination in Type-2 Diabetes · NCT06655740
Jun 30, 2027 (ESTIMATED) · Not phased · RF Vapor Ablation Retreatment of Duodenal Mucosa in Non-responders With Type-2 Diabetes Mellitus · NCT06724822

Estimated primary completion per ClinicalTrials.gov. Dates move.

Record	Title	Phase	Status	Start	Primary completion
NCT07355270	A U.S. Pilot Human Investigation of RadiofrEquency Vapor Ablation System to Evaluate Safety, TOleRability, and Effectiveness for Proximal Intestinal Mucosal Ablation in Patients With Type 2 Diabetes Mellitus (RESTORE-1 Study)	Not phased (device or behavioral study)	Recruiting	Apr 1, 2026	Dec 31, 2026 (estimated)
NCT06655740	Safety, Tolerability, and Effectiveness of Duodenal Mucosal RF Vapor Ablation for Insulin Elimination in Type-2 Diabetes	Not phased (device or behavioral study)	Active, not recruiting	Oct 1, 2024	Jun 30, 2027 (estimated)
NCT06724822	RF Vapor Ablation Retreatment of Duodenal Mucosa in Non-responders With Type-2 Diabetes Mellitus	Not phased (device or behavioral study)	Active, not recruiting	Nov 14, 2024	Jun 30, 2027 (estimated)
NCT05887635	Study of Duodenal Mucosal RF Vapor Ablation in Subjects With Type-2 Diabetes Mellitus	Not phased (device or behavioral study)	Recruiting	Sep 2, 2023	2026-01 (estimated)

Aug 8, 2025 FDA 510(k) clearance: Aqua Medical RF Vapor Ablation System — K251226, Aug 8, 2025. Applicant at approval: Aqua Medical, Inc. source ↗
Dec 12, 2024 FDA 510(k) clearance: Aqua Medical RF Vapor Ablation System — K241271, Dec 12, 2024. Applicant at approval: Aqua Medical, Inc. source ↗